Daily Chart: Phase III remdesivir data in severe COVID-19
Data from a trio of Phase III studies of remdesivir from Gilead Sciences Inc. (NASDAQ:GILD) in patients with severe COVID-19 were released Wednesday. Participants in all three studies received 200 mg remdesivir on day one, followed by 100 mg daily for the remainder of the treatment course.
Subgroup analyses based on number of symptomatic days before treatment onset provide hints regarding the optimal patient populations for the antiviral.
Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus. The content is free to all who visit the site.